Efficacy of Solifenacin and trospium chloride on neurogenic bladder

Phase 4

• Conditions: Condition 1: stroke. Condition 2: neurogenic bladder.; Cerebrovascular disease, unspecified; Neuromuscular dysfunction of bladder, unspecified; I67.9; N31.9

• Registration Number: IRCT20160606028304N2
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 201

Inclusion Criteria

Stroke diagnosis patients
Normal cognitive function
Lower urinary tract symptomes
Patients with CVA should be ambulatory, able to communicate, and record a voiding diary
age =18 years

Exclusion Criteria

Evidence of brain stem or bilateral signs on examination
Mental disorders according to the patient's own statement
Having history of LUTS surgery, pelvic and urologic surgery, or trauma
Other severe neurological disease including dementia
Severe psychiatric disease
Prostate cancer
Patients who refuse consent
Abnormal liver function
severe constipation
patiensts with previous history of hypersensitivity reaction to anticholinergics or closed anterior chamber glaucoma

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
BSS score. Timepoint: begining of study and 4 weeks after intervention. Method of measurement: questionnaire.;ICIQ-UI score. Timepoint: begining of study and 4 weeks after intervention. Method of measurement: questionnaire.;I-QOL test score. Timepoint: begining of study and 4 weeks after intervention. Method of measurement: questionnaire.